Proteologics Reports Progress in Research Collaboration with Teva Pharmaceutical Industries Ltd.REHOVOT, Israel -- Proteologics Ltd., a leader in ubiquitin u·biq·ui·tin n. A polypeptide found in all eukaryotic cells, including plant cells, that participates in a variety of cellular functions including protein degradation. research, announces the achievement of a major milestone in its collaboration with Teva. The alliance fortifies companies' efforts in research, development and commercialization of novel anti-cancer therapeutics. Proteologics and Teva partner in two independent, yet complementary projects, focusing on specific components of the ubiquitin system. Successful identification and validation of a novel target triggered entrance into the second phase of the collaboration moving ahead into drug discovery. This progress follows the accomplishments of another joint Proteologics and Teva project, whereby small molecules are expected to enter animal tests later next year. Under the agreement Proteologics is responsible for the research and early drug discovery activities while Teva retains the option to continue development through preclinical and clinical phases, as well as commercialization of products. Proteologics shall be entitled to payments pending on the achievements of clinical development milestones, as well as royalties from sales. "The achievement of this Milestone in agreement with Teva demonstrates Proteologics' ubiquitin expertise and strong drug discovery capabilities," said Proteologics CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Mr. Avishai Levy. "We are pleased to be working side by side with world's key pharmaceutical player in search for promising anti-cancer therapeutics." About Proteologics Inc. Proteologics is a leading force in investigating the ubiquitin system for the discovery and development of novel therapeutics. Drs. Avram Hershko Avram Hershko (Hebrew: אברהם הרשקו, born Herskó Ferenc, 31 December 1937) is an Israeli biochemist. and Aaron Ciechanover Aaron Ciechanover (אהרון צ'חנובר) (born October 1, 1947) is an Israeli biologist, and Nobel Prize in Chemistry laureate for his discovery with Avram Hershko and Irwin Rose, of ubiquitin-mediated protein degradation. - the 2004 Nobel Prize in chemistry The Nobel Prize in Chemistry (Swedish: Nobelpriset i kemi) is awarded once a year by the Royal Swedish Academy of Sciences. It is one of the six Nobel Prizes. The first prize was awarded in 1901. laureates for the discovery of the ubiquitin system - direct the company's scientific advisory board. Specific components of the ubiqutin pathway, such as E3's, are believed to offer novel targets for cancer, viral diseases, and CNS See Continuous net settlement. CNS See continuous net settlement (CNS). related pathologies. The unique know-how, biocheminformatics, and advanced technologies constitute Proteologics Proprietary Target & Drug Discovery Platform. Concurrent with major efforts in small molecule development, Proteologics pioneers the implementation of siRNA technology into the therapeutic pipeline. At present, Proteologics propels programs aimed at identifying novel, broad-spectrum antiviral drugs Antiviral Drugs Definition Antiviral drugs are medicines that cure or control virus infections. Purpose Antivirals are used to treat infections caused by viruses. to provide more effective treatment against drug-resistant HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and a variety of other viruses. The company also develops therapeutic agents to interfere at specific pathways relevant to several cancers. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion